Country for PR: United States
Contributor: PR Newswire New York
Tuesday, June 30 2020 - 22:10
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing
SAN DIEGO, June 30, 2020 /PRNewswire-AsiaNet/ --

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of 
biopharmaceutical contract development and manufacturing services, is pleased 
to announce the launch of AJILITY(TM), a flexible and agile drug product 
manufacturing platform, designed to advance vaccines and therapies to market by 
minimizing time to production. 

Logo - 

Aji Bio-Pharma's AJILITY platform is designed for novel therapeutics/vaccines 
and existing drug products with a new indication that can be used in COVID-19 
trials, FDA Emergency Use Authorizations (EUA), or other programs, providing 
enhanced flexibility by leveraging our existing, streamlined project 
configurations.  With Aji Bio-Pharma's AJILITY, clients will have access to our 
experience and expertise to guide them through decisions from components and 
excipients to method qualifications. The goal of the AJILITY platform is to 
minimize variables during tech transfer, manufacturing and shipping processes 
and rely on our regulatory expertise to navigate traditional production hurdles 
to quickly get therapies to clinics.  

"The AJILITY platform offers flexibility and time savings, which is an enormous 
boost those clients with drug products that need to get to clinical trials 
quickly," said Dustin Campbell, Associate Director of Commercial Operations at 
Ajinomoto Bio-Pharma Services. "As a leading CDMO for drug product 
manufacturing, we understand that some program details affect the manufacturing 
timeline more than others. The AJILITY platform utilizes Aji Bio-Pharma's 
extensive experience in manufacturing and regulatory insight to fast track our 
clients' programs to market." 

"We are excited to introduce the AJILITY platform to our client base interested 
in our progressive partnering approach to advance their therapeutic to 
patients," said Kristin DeFife, Ph.D., Sr. VP of Operations & Site Head at 
Ajinomoto Bio-Pharma Services. "The AJILITY platform was developed by a 
cross-functional departmental team to provide our clients access to preferred 
drug product manufacturing processes, coupled with our expertise in regulatory 
submissions, process development, and shipping configurations at our San Diego, 
California facility." 

To learn more about the AJILITY program, visit: 

About Ajinomoto Bio-Pharma Services 
Ajinomoto Bio-Pharma Services is a fully integrated contract development and 
manufacturing organization with sites in Belgium, United States, Japan, and 
India, providing comprehensive development, cGMP manufacturing, and aseptic 
fill finish services for small and large molecule APIs and intermediates. 
Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and 
capabilities for pre-clinical and pilot programs to commercial quantities, 
including Corynex(R) protein expression technology, oligonucleotide synthesis, 
antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, 
continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is 
dedicated to providing a high level of quality and service to meet our client's 
needs. Learn more: 

SOURCE: Ajinomoto Bio-Pharma Services